[
    {
        "operation": "isolate",
        "reagent": "bone from femurs and tibias of 8-12 Pac-1-/- and Pac-1+/+ week old mice",
        "equipment": "None",
        "condition": "None",
        "origin": "1. Maturate mast cells from bone marrow using interleukin 3. Isolate bone from femurs and tibias of 8-12 Pac-1-/- and Pac-1+/+ week old mice.  Grow cells at 4&#xD7;10<sup>5</sup> cells/mL in RPMI 1640 medium \\(Life Technologies, Rockville) supplemented with 10% fetal bovine serum \\(HyClone, Logan), 100 &#x3BC;g each of penicillin and streptomycin per mL, 2mM L-glutamine \\(Life Technologies), 50 &#x3BC;M &#x3B2;-mercaptoethanol, 1% HEPES and 5 ng/mL of recombinant murine IL-3 \\(Peprotech) for 4-6 weeks at 37<sup>o</sup>C in 5% CO2.  By 4-6 weeks in culture, greater than 98% of cells should be c-kit and Fc&#x3B5;RI positive as assessed by fluorescein isothiocyanate \\(FITC)-labelled anti-c-kit \\(BD, Pharmingen) and anti-DNP IgE \\(Sigma) antibodies respectively using Flow Cytometry.  Cell morphology should also be assessed by cytospin and staining with giemsa and toluidine blue.  To stimulate, sensitise cells with anti-DNP IgE mAb \\(100 ng/mL, Sigma) for 18 hours, wash twice to remove unbound IgE and stimulate with 20 ng/mL of DNP-HSA \\(Sigma) for chosen times.\r"
    },
    {
        "operation": "grow",
        "reagent": "RPMI 1640 medium, fetal bovine serum, penicillin, streptomycin, L-glutamine, &#x3B2;-mercaptoethanol, HEPES, recombinant murine IL-3",
        "equipment": "CO2 incubator",
        "condition": "4-6 weeks at 37<sup>o</sup>C in 5% CO2",
        "origin": "1. Maturate mast cells from bone marrow using interleukin 3. Isolate bone from femurs and tibias of 8-12 Pac-1-/- and Pac-1+/+ week old mice.  Grow cells at 4&#xD7;10<sup>5</sup> cells/mL in RPMI 1640 medium \\(Life Technologies, Rockville) supplemented with 10% fetal bovine serum \\(HyClone, Logan), 100 &#x3BC;g each of penicillin and streptomycin per mL, 2mM L-glutamine \\(Life Technologies), 50 &#x3BC;M &#x3B2;-mercaptoethanol, 1% HEPES and 5 ng/mL of recombinant murine IL-3 \\(Peprotech) for 4-6 weeks at 37<sup>o</sup>C in 5% CO2.  By 4-6 weeks in culture, greater than 98% of cells should be c-kit and Fc&#x3B5;RI positive as assessed by fluorescein isothiocyanate \\(FITC)-labelled anti-c-kit \\(BD, Pharmingen) and anti-DNP IgE \\(Sigma) antibodies respectively using Flow Cytometry.  Cell morphology should also be assessed by cytospin and staining with giemsa and toluidine blue.  To stimulate, sensitise cells with anti-DNP IgE mAb \\(100 ng/mL, Sigma) for 18 hours, wash twice to remove unbound IgE and stimulate with 20 ng/mL of DNP-HSA \\(Sigma) for chosen times.\r"
    },
    {
        "operation": "label",
        "reagent": "anti-DNP IgE mAb, FITC-labelled anti-c-kit, anti-DNP IgE antibodies",
        "equipment": "Flow Cytometry",
        "condition": "None",
        "origin": "1. Maturate mast cells from bone marrow using interleukin 3. Isolate bone from femurs and tibias of 8-12 Pac-1-/- and Pac-1+/+ week old mice.  Grow cells at 4&#xD7;10<sup>5</sup> cells/mL in RPMI 1640 medium \\(Life Technologies, Rockville) supplemented with 10% fetal bovine serum \\(HyClone, Logan), 100 &#x3BC;g each of penicillin and streptomycin per mL, 2mM L-glutamine \\(Life Technologies), 50 &#x3BC;M &#x3B2;-mercaptoethanol, 1% HEPES and 5 ng/mL of recombinant murine IL-3 \\(Peprotech) for 4-6 weeks at 37<sup>o</sup>C in 5% CO2.  By 4-6 weeks in culture, greater than 98% of cells should be c-kit and Fc&#x3B5;RI positive as assessed by fluorescein isothiocyanate \\(FITC)-labelled anti-c-kit \\(BD, Pharmingen) and anti-DNP IgE \\(Sigma) antibodies respectively using Flow Cytometry.  Cell morphology should also be assessed by cytospin and staining with giemsa and toluidine blue.  To stimulate, sensitise cells with anti-DNP IgE mAb \\(100 ng/mL, Sigma) for 18 hours, wash twice to remove unbound IgE and stimulate with 20 ng/mL of DNP-HSA \\(Sigma) for chosen times.\r"
    },
    {
        "operation": "stain",
        "reagent": "giemsa and toluidine blue",
        "equipment": "cytospin",
        "condition": "None",
        "origin": "1. Maturate mast cells from bone marrow using interleukin 3. Isolate bone from femurs and tibias of 8-12 Pac-1-/- and Pac-1+/+ week old mice.  Grow cells at 4&#xD7;10<sup>5</sup> cells/mL in RPMI 1640 medium \\(Life Technologies, Rockville) supplemented with 10% fetal bovine serum \\(HyClone, Logan), 100 &#x3BC;g each of penicillin and streptomycin per mL, 2mM L-glutamine \\(Life Technologies), 50 &#x3BC;M &#x3B2;-mercaptoethanol, 1% HEPES and 5 ng/mL of recombinant murine IL-3 \\(Peprotech) for 4-6 weeks at 37<sup>o</sup>C in 5% CO2.  By 4-6 weeks in culture, greater than 98% of cells should be c-kit and Fc&#x3B5;RI positive as assessed by fluorescein isothiocyanate \\(FITC)-labelled anti-c-kit \\(BD, Pharmingen) and anti-DNP IgE \\(Sigma) antibodies respectively using Flow Cytometry.  Cell morphology should also be assessed by cytospin and staining with giemsa and toluidine blue.  To stimulate, sensitise cells with anti-DNP IgE mAb \\(100 ng/mL, Sigma) for 18 hours, wash twice to remove unbound IgE and stimulate with 20 ng/mL of DNP-HSA \\(Sigma) for chosen times.\r"
    },
    {
        "operation": "sensitise",
        "reagent": "anti-DNP IgE mAb",
        "equipment": "None",
        "condition": "18 hours",
        "origin": "1. Maturate mast cells from bone marrow using interleukin 3. Isolate bone from femurs and tibias of 8-12 Pac-1-/- and Pac-1+/+ week old mice.  Grow cells at 4&#xD7;10<sup>5</sup> cells/mL in RPMI 1640 medium \\(Life Technologies, Rockville) supplemented with 10% fetal bovine serum \\(HyClone, Logan), 100 &#x3BC;g each of penicillin and streptomycin per mL, 2mM L-glutamine \\(Life Technologies), 50 &#x3BC;M &#x3B2;-mercaptoethanol, 1% HEPES and 5 ng/mL of recombinant murine IL-3 \\(Peprotech) for 4-6 weeks at 37<sup>o</sup>C in 5% CO2.  By 4-6 weeks in culture, greater than 98% of cells should be c-kit and Fc&#x3B5;RI positive as assessed by fluorescein isothiocyanate \\(FITC)-labelled anti-c-kit \\(BD, Pharmingen) and anti-DNP IgE \\(Sigma) antibodies respectively using Flow Cytometry.  Cell morphology should also be assessed by cytospin and staining with giemsa and toluidine blue.  To stimulate, sensitise cells with anti-DNP IgE mAb \\(100 ng/mL, Sigma) for 18 hours, wash twice to remove unbound IgE and stimulate with 20 ng/mL of DNP-HSA \\(Sigma) for chosen times.\r"
    },
    {
        "operation": "wash",
        "reagent": "anti-DNP IgE mAb",
        "equipment": "None",
        "condition": "twice to remove unbound IgE",
        "origin": "1. Maturate mast cells from bone marrow using interleukin 3. Isolate bone from femurs and tibias of 8-12 Pac-1-/- and Pac-1+/+ week old mice.  Grow cells at 4&#xD7;10<sup>5</sup> cells/mL in RPMI 1640 medium \\(Life Technologies, Rockville) supplemented with 10% fetal bovine serum \\(HyClone, Logan), 100 &#x3BC;g each of penicillin and streptomycin per mL, 2mM L-glutamine \\(Life Technologies), 50 &#x3BC;M &#x3B2;-mercaptoethanol, 1% HEPES and 5 ng/mL of recombinant murine IL-3 \\(Peprotech) for 4-6 weeks at 37<sup>o</sup>C in 5% CO2.  By 4-6 weeks in culture, greater than 98% of cells should be c-kit and Fc&#x3B5;RI positive as assessed by fluorescein isothiocyanate \\(FITC)-labelled anti-c-kit \\(BD, Pharmingen) and anti-DNP IgE \\(Sigma) antibodies respectively using Flow Cytometry.  Cell morphology should also be assessed by cytospin and staining with giemsa and toluidine blue.  To stimulate, sensitise cells with anti-DNP IgE mAb \\(100 ng/mL, Sigma) for 18 hours, wash twice to remove unbound IgE and stimulate with 20 ng/mL of DNP-HSA \\(Sigma) for chosen times.\r"
    },
    {
        "operation": "stimulate",
        "reagent": "DNP-HSA",
        "equipment": "None",
        "condition": "for chosen times",
        "origin": "1. Maturate mast cells from bone marrow using interleukin 3. Isolate bone from femurs and tibias of 8-12 Pac-1-/- and Pac-1+/+ week old mice.  Grow cells at 4&#xD7;10<sup>5</sup> cells/mL in RPMI 1640 medium \\(Life Technologies, Rockville) supplemented with 10% fetal bovine serum \\(HyClone, Logan), 100 &#x3BC;g each of penicillin and streptomycin per mL, 2mM L-glutamine \\(Life Technologies), 50 &#x3BC;M &#x3B2;-mercaptoethanol, 1% HEPES and 5 ng/mL of recombinant murine IL-3 \\(Peprotech) for 4-6 weeks at 37<sup>o</sup>C in 5% CO2.  By 4-6 weeks in culture, greater than 98% of cells should be c-kit and Fc&#x3B5;RI positive as assessed by fluorescein isothiocyanate \\(FITC)-labelled anti-c-kit \\(BD, Pharmingen) and anti-DNP IgE \\(Sigma) antibodies respectively using Flow Cytometry.  Cell morphology should also be assessed by cytospin and staining with giemsa and toluidine blue.  To stimulate, sensitise cells with anti-DNP IgE mAb \\(100 ng/mL, Sigma) for 18 hours, wash twice to remove unbound IgE and stimulate with 20 ng/mL of DNP-HSA \\(Sigma) for chosen times.\r"
    },
    {
        "operation": "transfect",
        "reagent": "pG5E4D38-Luc, BMMCs",
        "equipment": "Amaxa nucleofector device",
        "condition": "using solution T and program T-016",
        "origin": "2. For the measurement of transcriptional Elk-1 activity, transfect 4 x 10<sup>6</sup> BMMCs with 1.75 &#x3BC;g pG5E4D38&#x2013;Luc, 1.75 &#x3BC;g pSG-Gal-Elk-1 \\(both plasmids kindly provided by Dr. Peter Shaw, University of Nottingham, UK, Frost et al, 1997) and 1 &#x3BC;g of the lacZ-expression vector pCMV&#x3B2; \\(Clonetech, to allow standardization of the measured luciferase activity) using solution T and an Amaxa nucleofector device \\(K&#xF6;ln, Germany; set to program T-016). In addition, &#x201C;mock-transfect&#x201D;cells with PBS in order to measure the background luciferase and &#x3B2;-galactosidase activities. This Elk-1 reporter system is based on a hybrid fusion protein consisting of the DNA binding domain of the yeast transcription factor Gal4 and the transactivation domain of Elk-1 that binds via its Gal4 moiety to the pG5E4D38&#x2013;Luc plasmid and drives the transcription of the luciferase gene only if it is phosphorylated by ERK within its Elk-1 moiety \\(Kortenjann et al, 1994). \r"
    },
    {
        "operation": "transfect",
        "reagent": "pSG-Gal-Elk-1, BMMCs",
        "equipment": "Amaxa nucleofector device",
        "condition": "using solution T and program T-016",
        "origin": "2. For the measurement of transcriptional Elk-1 activity, transfect 4 x 10<sup>6</sup> BMMCs with 1.75 &#x3BC;g pG5E4D38&#x2013;Luc, 1.75 &#x3BC;g pSG-Gal-Elk-1 \\(both plasmids kindly provided by Dr. Peter Shaw, University of Nottingham, UK, Frost et al, 1997) and 1 &#x3BC;g of the lacZ-expression vector pCMV&#x3B2; \\(Clonetech, to allow standardization of the measured luciferase activity) using solution T and an Amaxa nucleofector device \\(K&#xF6;ln, Germany; set to program T-016). In addition, &#x201C;mock-transfect&#x201D;cells with PBS in order to measure the background luciferase and &#x3B2;-galactosidase activities. This Elk-1 reporter system is based on a hybrid fusion protein consisting of the DNA binding domain of the yeast transcription factor Gal4 and the transactivation domain of Elk-1 that binds via its Gal4 moiety to the pG5E4D38&#x2013;Luc plasmid and drives the transcription of the luciferase gene only if it is phosphorylated by ERK within its Elk-1 moiety \\(Kortenjann et al, 1994). \r"
    },
    {
        "operation": "transfect",
        "reagent": "lacZ-expression vector pCMVβ, BMMCs",
        "equipment": "Amaxa nucleofector device",
        "condition": "using solution T and program T-016",
        "origin": "2. For the measurement of transcriptional Elk-1 activity, transfect 4 x 10<sup>6</sup> BMMCs with 1.75 &#x3BC;g pG5E4D38&#x2013;Luc, 1.75 &#x3BC;g pSG-Gal-Elk-1 \\(both plasmids kindly provided by Dr. Peter Shaw, University of Nottingham, UK, Frost et al, 1997) and 1 &#x3BC;g of the lacZ-expression vector pCMV&#x3B2; \\(Clonetech, to allow standardization of the measured luciferase activity) using solution T and an Amaxa nucleofector device \\(K&#xF6;ln, Germany; set to program T-016). In addition, &#x201C;mock-transfect&#x201D;cells with PBS in order to measure the background luciferase and &#x3B2;-galactosidase activities. This Elk-1 reporter system is based on a hybrid fusion protein consisting of the DNA binding domain of the yeast transcription factor Gal4 and the transactivation domain of Elk-1 that binds via its Gal4 moiety to the pG5E4D38&#x2013;Luc plasmid and drives the transcription of the luciferase gene only if it is phosphorylated by ERK within its Elk-1 moiety \\(Kortenjann et al, 1994). \r"
    },
    {
        "operation": "add",
        "reagent": "PBS, BMMCs",
        "equipment": "None",
        "condition": "mock-transfect cells",
        "origin": "2. For the measurement of transcriptional Elk-1 activity, transfect 4 x 10<sup>6</sup> BMMCs with 1.75 &#x3BC;g pG5E4D38&#x2013;Luc, 1.75 &#x3BC;g pSG-Gal-Elk-1 \\(both plasmids kindly provided by Dr. Peter Shaw, University of Nottingham, UK, Frost et al, 1997) and 1 &#x3BC;g of the lacZ-expression vector pCMV&#x3B2; \\(Clonetech, to allow standardization of the measured luciferase activity) using solution T and an Amaxa nucleofector device \\(K&#xF6;ln, Germany; set to program T-016). In addition, &#x201C;mock-transfect&#x201D;cells with PBS in order to measure the background luciferase and &#x3B2;-galactosidase activities. This Elk-1 reporter system is based on a hybrid fusion protein consisting of the DNA binding domain of the yeast transcription factor Gal4 and the transactivation domain of Elk-1 that binds via its Gal4 moiety to the pG5E4D38&#x2013;Luc plasmid and drives the transcription of the luciferase gene only if it is phosphorylated by ERK within its Elk-1 moiety \\(Kortenjann et al, 1994). \r"
    },
    {
        "operation": "transfect",
        "reagent": "pCMVβ, BMMCs",
        "equipment": "None",
        "condition": "None",
        "origin": "3. For the measurement of transcriptional NFAT:AP-1 activity, transfect BMMCs with 1 &#x3BC;g pCMV&#x3B2; and 3.5 &#x3BC;g of the NFAT reporter plasmid pNFAT-Luc \\(kindly provided by Dr. Gerald Crabtree, Stanford University, Stanford, USA) as described above. This NFAT reporter carries three tandem copies of the distal NFAT:AP-1 composite element of the human IL-2 promotor \\(Durand et al, 1988), which were cloned upstream of the minimal IL-2 promotor \\(from position -89 to +51) and the luciferase reporter gene. Consequently, this reporter is only transactivated when both NFAT and AP-1 are present in the nucleus and assembled to a ternary complex \\(Fiering et al, 1990; Macian et al., 2001). This widely used reporter plasmid responds to all known NFAT family members and can be activated in a NFAT-dependent manner in a variety of cell types.\r"
    },
    {
        "operation": "transfect",
        "reagent": "NFAT reporter plasmid pNFAT-Luc, BMMCs",
        "equipment": "None",
        "condition": "None",
        "origin": "3. For the measurement of transcriptional NFAT:AP-1 activity, transfect BMMCs with 1 &#x3BC;g pCMV&#x3B2; and 3.5 &#x3BC;g of the NFAT reporter plasmid pNFAT-Luc \\(kindly provided by Dr. Gerald Crabtree, Stanford University, Stanford, USA) as described above. This NFAT reporter carries three tandem copies of the distal NFAT:AP-1 composite element of the human IL-2 promotor \\(Durand et al, 1988), which were cloned upstream of the minimal IL-2 promotor \\(from position -89 to +51) and the luciferase reporter gene. Consequently, this reporter is only transactivated when both NFAT and AP-1 are present in the nucleus and assembled to a ternary complex \\(Fiering et al, 1990; Macian et al., 2001). This widely used reporter plasmid responds to all known NFAT family members and can be activated in a NFAT-dependent manner in a variety of cell types.\r"
    },
    {
        "operation": "add",
        "reagent": "RPMI 1640 medium, culture medium",
        "equipment": "None",
        "condition": "supplemented with 10% fetal bovine serum, 100 µg/mL penicillin, 100 µg/mL streptomycin, 2mM L-glutamine, 50 µM β-mercaptoethanol, 1% HEPES, and 5 ng/mL recombinant murine IL-3",
        "origin": "4.Following transfection with reporter plasmids, plate BMMCs in 3 mL culture medium \\(RPMI 1640 medium \\(Life Technologies) supplemented with 10% fetal bovine serum \\(HyClone), 100 &#x3BC;g each of penicillin and streptomycin per mL, 2mM L-glutamine \\(Life Technologies), 50 &#x3BC;M &#x3B2;-mercaptoethanol, 1% HEPES and 5 ng/mL of recombinant murine IL-3 \\(Peprotech)) and allow to recover for 24 h. Then sensitise with 100 ng/mL anti-DNP IgE antibodies for 18 hours. Subsequently, split the cells and either stimulate with 20 ng/mL DNP-HSA for 6 h \\(Elk-1) or 8 h \\(NFAT:AP-1) or leave untreated. Following stimulation, lyse the cells in luciferase lysis buffer \\(Promega) and determine the raw luciferase activities using a luciferase activity kit \\(Promega). As an internal control for transfection efficiency, measure the &#x3B2;-galactosidase \\(&#x3B2;-gal) activities using Galactostar and Galacton reagents \\(Tropix). The background &#x3B2;-gal activity of mock-transfected cells should be subtracted from the lysates of transfected BMMCs and the relative &#x3B2;-gal activity of each sample was calculated. In order to obtain the standardised luciferase activity, divide the luciferase activity of each sample by the corresponding relative &#x3B2;-gal activity.\r"
    },
    {
        "operation": "add",
        "reagent": "anti-DNP IgE antibodies, BMMCs",
        "equipment": "None",
        "condition": "18 hours of sensitization",
        "origin": "4.Following transfection with reporter plasmids, plate BMMCs in 3 mL culture medium \\(RPMI 1640 medium \\(Life Technologies) supplemented with 10% fetal bovine serum \\(HyClone), 100 &#x3BC;g each of penicillin and streptomycin per mL, 2mM L-glutamine \\(Life Technologies), 50 &#x3BC;M &#x3B2;-mercaptoethanol, 1% HEPES and 5 ng/mL of recombinant murine IL-3 \\(Peprotech)) and allow to recover for 24 h. Then sensitise with 100 ng/mL anti-DNP IgE antibodies for 18 hours. Subsequently, split the cells and either stimulate with 20 ng/mL DNP-HSA for 6 h \\(Elk-1) or 8 h \\(NFAT:AP-1) or leave untreated. Following stimulation, lyse the cells in luciferase lysis buffer \\(Promega) and determine the raw luciferase activities using a luciferase activity kit \\(Promega). As an internal control for transfection efficiency, measure the &#x3B2;-galactosidase \\(&#x3B2;-gal) activities using Galactostar and Galacton reagents \\(Tropix). The background &#x3B2;-gal activity of mock-transfected cells should be subtracted from the lysates of transfected BMMCs and the relative &#x3B2;-gal activity of each sample was calculated. In order to obtain the standardised luciferase activity, divide the luciferase activity of each sample by the corresponding relative &#x3B2;-gal activity.\r"
    },
    {
        "operation": "split",
        "reagent": "BMMCs",
        "equipment": "None",
        "condition": "after 24 hours of recovery",
        "origin": "4.Following transfection with reporter plasmids, plate BMMCs in 3 mL culture medium \\(RPMI 1640 medium \\(Life Technologies) supplemented with 10% fetal bovine serum \\(HyClone), 100 &#x3BC;g each of penicillin and streptomycin per mL, 2mM L-glutamine \\(Life Technologies), 50 &#x3BC;M &#x3B2;-mercaptoethanol, 1% HEPES and 5 ng/mL of recombinant murine IL-3 \\(Peprotech)) and allow to recover for 24 h. Then sensitise with 100 ng/mL anti-DNP IgE antibodies for 18 hours. Subsequently, split the cells and either stimulate with 20 ng/mL DNP-HSA for 6 h \\(Elk-1) or 8 h \\(NFAT:AP-1) or leave untreated. Following stimulation, lyse the cells in luciferase lysis buffer \\(Promega) and determine the raw luciferase activities using a luciferase activity kit \\(Promega). As an internal control for transfection efficiency, measure the &#x3B2;-galactosidase \\(&#x3B2;-gal) activities using Galactostar and Galacton reagents \\(Tropix). The background &#x3B2;-gal activity of mock-transfected cells should be subtracted from the lysates of transfected BMMCs and the relative &#x3B2;-gal activity of each sample was calculated. In order to obtain the standardised luciferase activity, divide the luciferase activity of each sample by the corresponding relative &#x3B2;-gal activity.\r"
    },
    {
        "operation": "stimulate",
        "reagent": "DNP-HSA, BMMCs",
        "equipment": "None",
        "condition": "6 hours for Elk-1 or 8 hours for NFAT:AP-1",
        "origin": "4.Following transfection with reporter plasmids, plate BMMCs in 3 mL culture medium \\(RPMI 1640 medium \\(Life Technologies) supplemented with 10% fetal bovine serum \\(HyClone), 100 &#x3BC;g each of penicillin and streptomycin per mL, 2mM L-glutamine \\(Life Technologies), 50 &#x3BC;M &#x3B2;-mercaptoethanol, 1% HEPES and 5 ng/mL of recombinant murine IL-3 \\(Peprotech)) and allow to recover for 24 h. Then sensitise with 100 ng/mL anti-DNP IgE antibodies for 18 hours. Subsequently, split the cells and either stimulate with 20 ng/mL DNP-HSA for 6 h \\(Elk-1) or 8 h \\(NFAT:AP-1) or leave untreated. Following stimulation, lyse the cells in luciferase lysis buffer \\(Promega) and determine the raw luciferase activities using a luciferase activity kit \\(Promega). As an internal control for transfection efficiency, measure the &#x3B2;-galactosidase \\(&#x3B2;-gal) activities using Galactostar and Galacton reagents \\(Tropix). The background &#x3B2;-gal activity of mock-transfected cells should be subtracted from the lysates of transfected BMMCs and the relative &#x3B2;-gal activity of each sample was calculated. In order to obtain the standardised luciferase activity, divide the luciferase activity of each sample by the corresponding relative &#x3B2;-gal activity.\r"
    },
    {
        "operation": "lyse",
        "reagent": "BMMCs, luciferase lysis buffer",
        "equipment": "None",
        "condition": "following stimulation",
        "origin": "4.Following transfection with reporter plasmids, plate BMMCs in 3 mL culture medium \\(RPMI 1640 medium \\(Life Technologies) supplemented with 10% fetal bovine serum \\(HyClone), 100 &#x3BC;g each of penicillin and streptomycin per mL, 2mM L-glutamine \\(Life Technologies), 50 &#x3BC;M &#x3B2;-mercaptoethanol, 1% HEPES and 5 ng/mL of recombinant murine IL-3 \\(Peprotech)) and allow to recover for 24 h. Then sensitise with 100 ng/mL anti-DNP IgE antibodies for 18 hours. Subsequently, split the cells and either stimulate with 20 ng/mL DNP-HSA for 6 h \\(Elk-1) or 8 h \\(NFAT:AP-1) or leave untreated. Following stimulation, lyse the cells in luciferase lysis buffer \\(Promega) and determine the raw luciferase activities using a luciferase activity kit \\(Promega). As an internal control for transfection efficiency, measure the &#x3B2;-galactosidase \\(&#x3B2;-gal) activities using Galactostar and Galacton reagents \\(Tropix). The background &#x3B2;-gal activity of mock-transfected cells should be subtracted from the lysates of transfected BMMCs and the relative &#x3B2;-gal activity of each sample was calculated. In order to obtain the standardised luciferase activity, divide the luciferase activity of each sample by the corresponding relative &#x3B2;-gal activity.\r"
    },
    {
        "operation": "measure",
        "reagent": "Galactostar and Galacton reagents, lysates of transfected BMMCs",
        "equipment": "None",
        "condition": "for β-galactosidase activity",
        "origin": "4.Following transfection with reporter plasmids, plate BMMCs in 3 mL culture medium \\(RPMI 1640 medium \\(Life Technologies) supplemented with 10% fetal bovine serum \\(HyClone), 100 &#x3BC;g each of penicillin and streptomycin per mL, 2mM L-glutamine \\(Life Technologies), 50 &#x3BC;M &#x3B2;-mercaptoethanol, 1% HEPES and 5 ng/mL of recombinant murine IL-3 \\(Peprotech)) and allow to recover for 24 h. Then sensitise with 100 ng/mL anti-DNP IgE antibodies for 18 hours. Subsequently, split the cells and either stimulate with 20 ng/mL DNP-HSA for 6 h \\(Elk-1) or 8 h \\(NFAT:AP-1) or leave untreated. Following stimulation, lyse the cells in luciferase lysis buffer \\(Promega) and determine the raw luciferase activities using a luciferase activity kit \\(Promega). As an internal control for transfection efficiency, measure the &#x3B2;-galactosidase \\(&#x3B2;-gal) activities using Galactostar and Galacton reagents \\(Tropix). The background &#x3B2;-gal activity of mock-transfected cells should be subtracted from the lysates of transfected BMMCs and the relative &#x3B2;-gal activity of each sample was calculated. In order to obtain the standardised luciferase activity, divide the luciferase activity of each sample by the corresponding relative &#x3B2;-gal activity.\r"
    },
    {
        "operation": "subtract",
        "reagent": "mock-transfected cells, lysates of transfected BMMCs",
        "equipment": "None",
        "condition": "for background β-galactosidase activity",
        "origin": "4.Following transfection with reporter plasmids, plate BMMCs in 3 mL culture medium \\(RPMI 1640 medium \\(Life Technologies) supplemented with 10% fetal bovine serum \\(HyClone), 100 &#x3BC;g each of penicillin and streptomycin per mL, 2mM L-glutamine \\(Life Technologies), 50 &#x3BC;M &#x3B2;-mercaptoethanol, 1% HEPES and 5 ng/mL of recombinant murine IL-3 \\(Peprotech)) and allow to recover for 24 h. Then sensitise with 100 ng/mL anti-DNP IgE antibodies for 18 hours. Subsequently, split the cells and either stimulate with 20 ng/mL DNP-HSA for 6 h \\(Elk-1) or 8 h \\(NFAT:AP-1) or leave untreated. Following stimulation, lyse the cells in luciferase lysis buffer \\(Promega) and determine the raw luciferase activities using a luciferase activity kit \\(Promega). As an internal control for transfection efficiency, measure the &#x3B2;-galactosidase \\(&#x3B2;-gal) activities using Galactostar and Galacton reagents \\(Tropix). The background &#x3B2;-gal activity of mock-transfected cells should be subtracted from the lysates of transfected BMMCs and the relative &#x3B2;-gal activity of each sample was calculated. In order to obtain the standardised luciferase activity, divide the luciferase activity of each sample by the corresponding relative &#x3B2;-gal activity.\r"
    },
    {
        "operation": "calculate",
        "reagent": "lysates of transfected BMMCs",
        "equipment": "None",
        "condition": "for relative β-galactosidase activity",
        "origin": "4.Following transfection with reporter plasmids, plate BMMCs in 3 mL culture medium \\(RPMI 1640 medium \\(Life Technologies) supplemented with 10% fetal bovine serum \\(HyClone), 100 &#x3BC;g each of penicillin and streptomycin per mL, 2mM L-glutamine \\(Life Technologies), 50 &#x3BC;M &#x3B2;-mercaptoethanol, 1% HEPES and 5 ng/mL of recombinant murine IL-3 \\(Peprotech)) and allow to recover for 24 h. Then sensitise with 100 ng/mL anti-DNP IgE antibodies for 18 hours. Subsequently, split the cells and either stimulate with 20 ng/mL DNP-HSA for 6 h \\(Elk-1) or 8 h \\(NFAT:AP-1) or leave untreated. Following stimulation, lyse the cells in luciferase lysis buffer \\(Promega) and determine the raw luciferase activities using a luciferase activity kit \\(Promega). As an internal control for transfection efficiency, measure the &#x3B2;-galactosidase \\(&#x3B2;-gal) activities using Galactostar and Galacton reagents \\(Tropix). The background &#x3B2;-gal activity of mock-transfected cells should be subtracted from the lysates of transfected BMMCs and the relative &#x3B2;-gal activity of each sample was calculated. In order to obtain the standardised luciferase activity, divide the luciferase activity of each sample by the corresponding relative &#x3B2;-gal activity.\r"
    },
    {
        "operation": "divide",
        "reagent": "luciferase activity of each sample, corresponding relative β-galactosidase activity",
        "equipment": "None",
        "condition": "to obtain standardized luciferase activity",
        "origin": "4.Following transfection with reporter plasmids, plate BMMCs in 3 mL culture medium \\(RPMI 1640 medium \\(Life Technologies) supplemented with 10% fetal bovine serum \\(HyClone), 100 &#x3BC;g each of penicillin and streptomycin per mL, 2mM L-glutamine \\(Life Technologies), 50 &#x3BC;M &#x3B2;-mercaptoethanol, 1% HEPES and 5 ng/mL of recombinant murine IL-3 \\(Peprotech)) and allow to recover for 24 h. Then sensitise with 100 ng/mL anti-DNP IgE antibodies for 18 hours. Subsequently, split the cells and either stimulate with 20 ng/mL DNP-HSA for 6 h \\(Elk-1) or 8 h \\(NFAT:AP-1) or leave untreated. Following stimulation, lyse the cells in luciferase lysis buffer \\(Promega) and determine the raw luciferase activities using a luciferase activity kit \\(Promega). As an internal control for transfection efficiency, measure the &#x3B2;-galactosidase \\(&#x3B2;-gal) activities using Galactostar and Galacton reagents \\(Tropix). The background &#x3B2;-gal activity of mock-transfected cells should be subtracted from the lysates of transfected BMMCs and the relative &#x3B2;-gal activity of each sample was calculated. In order to obtain the standardised luciferase activity, divide the luciferase activity of each sample by the corresponding relative &#x3B2;-gal activity.\r"
    },
    {
        "operation": "transfect",
        "reagent": "WT Pac-1, mast cells",
        "equipment": "None",
        "condition": "over-expression or rescue experiments",
        "origin": "5. For over-expression or rescue experiments, transfect mast cells with 2ug of WT Pac-1, C257S Pac-1 or pMIG vector control."
    },
    {
        "operation": "transfect",
        "reagent": "C257S Pac-1, mast cells",
        "equipment": "None",
        "condition": "over-expression or rescue experiments",
        "origin": "5. For over-expression or rescue experiments, transfect mast cells with 2ug of WT Pac-1, C257S Pac-1 or pMIG vector control."
    },
    {
        "operation": "transfect",
        "reagent": "pMIG vector control, mast cells",
        "equipment": "None",
        "condition": "over-expression or rescue experiments",
        "origin": "5. For over-expression or rescue experiments, transfect mast cells with 2ug of WT Pac-1, C257S Pac-1 or pMIG vector control."
    }
]